ImmuPharma Quick Reference Sheet following new Lupuzor licence

© 2019 by Capital Access Group.

  • Black Twitter Icon
  • Black LinkedIn Icon
  • Capital Access

ImmuPharma Quick Reference Sheet following new Lupuzor licence


Following the recent announcement that Avion Pharmaceuticals has entered into a licence to pay up to $25m to develop (through the second phase III trial) and commercialise its major drug Lupuzor ™, ImmuPharma presents a very different opportunity compared to even a few weeks ago.


Read the full sheet here.

58 views